Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.64 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18174438 | 0.89 | NFE2L2 (0.66) | NFE2L2HCAR2KEAP1TNFKDM4E | |
| SCHEMBL17507307 | 0.87 | NFE2L2 (0.64) | NFE2L2HCAR2KEAP1TNFKDM4E | |
| SCHEMBL17507280 | 0.87 | NFE2L2 (0.64) | NFE2L2HCAR2KEAP1TNFKDM4E | |
| SCHEMBL18174415 | 0.86 | NFE2L2 (0.63) | NFE2L2HCAR2KEAP1TNF | |
| SCHEMBL18174429 | 0.86 | NFE2L2 (0.62) | NFE2L2HCAR2KEAP1TNFKDM4E | |
| SCHEMBL18174424 | 0.86 | NFE2L2 (0.67) | NFE2L2HCAR2KEAP1TNFKDM4E | |
| SCHEMBL18174422 | 0.86 | NFE2L2 (0.67) | NFE2L2HCAR2KEAP1TNFKDM4E | |
| SCHEMBL17507309 | 0.86 | NFE2L2 (0.62) | NFE2L2HCAR2KEAP1TNFKDM4E | |
| SCHEMBL18174431 | 0.86 | NFE2L2 (0.62) | NFE2L2HCAR2KEAP1TNFKDM4E | |
| SCHEMBL18174445 | 0.86 | NFE2L2 (0.62) | NFE2L2HCAR2KEAP1TNFKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071271-A1 | Fumarate Analogs and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-03-15 | — | — | US | disclosed |
| US-9801866-B2 | Fumarate analogs and uses thereof | Rigl Pharmaceutical, Inc. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170065569-A1 | Fumarate Analogs and Uses Thereof | MIDCAP FINANCIAL TRUST | 2017-03-09 | — | — | US | disclosed |
| US-9475781-B2 | Fumarate analogs and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071271-A1 | Fumarate Analogs and Uses Thereof | FH, GLS, FPGS | NFE2L2 205/4885HCAR2 737/4885KEAP1 344/4885 |
| US-20170065569-A1 | Fumarate Analogs and Uses Thereof | FH, GLS, FPGS | NFE2L2 205/4885HCAR2 737/4885KEAP1 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.